Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia

In a large multicenter randomized controlled trial, critically ill adults undergoing invasive mechanical ventilation for at least 72 hours received inhaled amikacin or placebo for 3 days. The intervention aimed to prevent ventilator-associated pneumonia (VAP). Among 847 analyzed patients, inhaled amikacin significantly reduced the incidence of VAP over 28 days (15% vs. 22%; P=0.004), including cases due to amikacin-susceptible gram-negative bacteria. Serious adverse effects were uncommon, and the intervention showed promising benefit in reducing VAP burden, even when factoring in competing risks like extubation and death

In a large multicenter randomized controlled trial, critically ill adults undergoing invasive mechanical ventilation for at least 72 hours received inhaled amikacin or placebo for 3 days. The intervention aimed to prevent ventilator-associated pneumonia (VAP). Among 847 analyzed patients, inhaled amikacin significantly reduced the incidence of VAP over 28 days (15% vs. 22%; P=0.004), including cases due to amikacin-susceptible gram-negative bacteria. Serious adverse effects were uncommon, and the intervention showed promising benefit in reducing VAP burden, even when factoring in competing risks like extubation and death